Khan R M M,Chua Z J Y,Tan J C,et al. From pre-diabetesto diabetes :diagnosis, treatments and translational research[J].Medicina (Kaunas),2019,55(9):546.
[2]
Barragán I P,Oidor C V H,Loeza A E,et al. Evaluation of the neonatal streptozotocin model of diabetes in rats: evidence for a model of neuropathic pain[J].Pharmacol Rep,2018,70(2):294-303.
[3]
Nguyen N,Takemoto J K. A case for alpha-lipoic acid as an alternative treatment for diabetic polyneuropathy[J].J Pharm Pharm Sci,2018,21(1s):177s-191s.
[4]
Ghaemi N,Hasanabadi H,Ashrafzadeh F,et al.Peripheral neuropathy in children and adolescents with insulin-dependent diabetes mellitus[J].Iran J Child Neurol,2018,12(2):83-90.
[5]
Shamsaldeen Y A,Mackenzie L S,Lione L A,et al. Methylglyoxal, a metabolite increased in diabetes is associated with insulin resistance, vascular dysfunction and neuropathies[J].Curr Drug Metab,2016,17(4): 359-367.
[6]
Lee J Y,Choi H Y,Park C S,et al.GS-KG9 ameliorates diabetic neuropathic pain induced by streptozotocin in rats[J].J Ginseng Res,2019,43(1):58-67.
[7]
Kaur N,Kishore L, Singh R.Chromane isolated from leaves of dilleniaindica improves the neuronal dysfunction in STZ-induced diabetic neuropathy[J].J Ethnopharmacol,2017,12(206):19-30.
[8]
Prnova M S,Kovacikova L,Svik K,et al.Triglyceride-lowering effect of the aldose reductaseinhibitor cemtirestat-anotherfactorthat maycontributeto attenuation of symptoms of peripheral neuropathy in STZ-diabetic rats[J].Naunyn Schmiedebergs Arch Pharmacol,2020,394(4):651-661.
[9]
Luo L,Zhou W H,Cai J J,et al.Gene expression profiling identifies downregulation of the neurotrophin-MAPK signaling pathway in female diabetic peripheral neuropathy patients[J].J Diabetes Res, 2017,2017:8103904.
[10]
Callaghan B C, Little A A,Feldman E L,etal.Enhanced glucose control for preventing and treating diabetic neuropathy[J].Cochrane Database Syst Rev,2012,13(6):CD007543.
[11]
Holman R R,Paul S K,Bethel M A,et al.10-year follow-up of intensive glucose control in type 2 diabetes[J].N Engl J Med,2008,359(15):1577-1589.
[12]
Chahbi Z,Lahmar B, Hadri S E,et al.The prevalence of painful diabetic neuropathy in 300 moroccan diabetics[J].Pan Afr Med J,2018,31: 158.
[13]
Griggs R B,Donahue R R,Adkins B G,et al.Pioglitazone inhibits the development of hyperalgesia and sensitization of spinal nociresponsive neurons in type 2 diabetes[J].J Pain,2016,17(3):359-373.
[14]
Tracey T J,Steyn F J,Wolvetang E J,et al.Neuronal lipid metabolism:multiple pathways driving functional outcomes in health and disease[J].Front Mol Neurosci,2018,11:10.
[15]
Yao L,Wu Y T,Tian G X,et al.Acrolein scavenger hydralazine prevents streptozotocin-induced painful diabetic neuropathy and spinal neuroinflammation in rats[J].Anat Rec (Hoboken),2017,300(10):1858-1864.
[16]
Singh J,Saha L,Singh N,et al.Study of nuclear factor-2 erythroid related factor-2 activator, berberine, in paclitaxel induced peripheral neuropathy pain model in rats[J]. J Pharm Pharmacol,2019,71(5):797-805.
[17]
Jiang Y,Ran X,Jia L,et al.Epidemiology of type 2 diabetic foot problems and predictive factors for amputation in China[J].Int J Low Extrem Wounds,2015,14(1):19-27.
[18]
Naqviss Z H,Imani S,Hosseinifard H,et al.Associations of serum low-density lipoprotein and systolic blood pressure levels with type 2 diabetic patients with and without peripheral neuropathy: systemic review, meta-analysis and meta-regression analysis of observational studies[J].BMC Endocr Disord,2019,19(1):125.
[19]
Yang C P,Lin C C,Li C I,et al.Cardiovascular risk factors increase the risks of diabetic peripheral neuropathy in patients with type 2 diabetes mellitus:the taiwan diabetes study[J].Medicine (Baltimore), 2015,94(42):e1783.
[20]
Garoushi S,Johnson M I,Tashani O A.A cross-sectional study to estimate the point prevalence of painful diabetic neuropathy in Eastern Libya[J].BMC Public Health,2019,19(1):78.
[21]
Huang J X,Liao Y F,Li Y M. Clinical features and microvascular complications risk factors of early-onset type 2 diabetes mellitus[J].Curr Med Sci,2019,39(5):754-758.
[22]
Çelik S B,Can H,Sözmen M K,et al.Evaluation of the neuropathic pain in the smokers[J].Agri,2017, 29(3):122-126.
[23]
Xia N,Morteza A,Yang F,et al.Review of the role of cigarette smoking in diabetic foot[J].J Diabetes Investig,2019,10(2):202-215.
[24]
Tamer A,Yildiz S,Yildiz N,et al.The prevalence of neuropathy and relationship with risk factors in diabetic patients: a single-center experience[J].Med Princ Pract,2006,15(3):190-194.
[25]
Grisold A,Callaghan B C,Feldman E L.Mediators of diabetic neuropathy: is hyperglycemia the only culprit?[J].Curr Opin Endocrinol Diabetes Obes,2017,24(2):103-111.
[26]
Yigit S,Karakus N,Inanir A.Association of MTHFR gene C677T mutation with diabetic peripheral neuropathy and diabetic retinopathy[J].Mol Vis,2013,19: 1626-1630.
[27]
Cardinez N,Lovblom L E,Bai J W,et al.Sex differences in neuropathic pain in longstanding diabetes: results from the canadian study of longevity in type 1 diabetes[J].J Diabetes Complications,2018,32(7): 660-664.
[28]
Liu X,Xu Y,An M,et al.The risk factors for diabetic peripheral neuropathy: a meta-analysis[J].PLoS One, 2019,14(2):e0212574.
[29]
Mohan V,Anjana R M,Ranjit U,et al.Clinical profile of elderly patients (over 90 years) with type 2 diabetes seen at a diabetes centre in South India[J].Diabetes Technol Ther,2020,22(2):79-84.
2020, Vol. 31 
